Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Missouri: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 215 | 40% |
| 2020 | 4 | 184 | 43% |
| 2021 | 5 | 198 | 48% |
| 2022 | 4 | 168 | 51% |
| 2023 | 5 | 174 | 55% |
| 2024 | 3 | 175 | 57% |
| 2025 from claims | – | 501 405–588 | 58% |
| 2026 forecast | – | 546 428–686 | 58% |
| 2027 forecast | – | 594 441–786 | 59% |
| 2028 forecast | – | 647 458–892 | 60% |
| 2029 forecast | – | 703 478–1,008 | 60% |
| 2030 forecast | – | 765 501–1,135 | 61% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Missouri; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 43% inpatient hospital, 17% hospital outpatient, 17% surgery center, 22% office.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 7 | 367+22%/yr | +22%/yr | 0.3 | 11% | 610 in 2030+8.7%/yr |
| Indiana | 3 | 192+9%/yr | +9%/yr | 0.2 | 27% | 430 in 2030+14%/yr |
| Minnesota | 3 | 178+21%/yr | +21%/yr | 0.3 | 41% | 350 in 2030+12%/yr |
| Illinois | 2 | 171+8.4%/yr | +8.4%/yr | 0.1 | 0% | 380 in 2030+14%/yr |
| Kansas | 5 | 149+26%/yr | +26%/yr | 0.3 | 50% | 80 in 2030−9.1%/yr |
| Wisconsin | 3 | 135+14%/yr | +14%/yr | 0.2 | 100% | 140 in 2030+0.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 56 | 2,193−7.1%/yr | −7.1%/yr | 3.41.1× | 5% | 2,190 in 20300%/yr |
| Lumbar fusion | 51 | 1,950−5.1%/yr | −5.1%/yr | 3.01.1× | 0% | 2,150 in 2030+1.6%/yr |
| Kyphoplasty & vertebroplasty | 13 | 1,235−7.5%/yr | −7.5%/yr | 2.01.5× | 5% | 1,060 in 2030−2.5%/yr |
| Cervical fusion & disc arthroplasty | 25 | 1,166−5.8%/yr | −5.8%/yr | 1.81.4× | 1% | 1,250 in 2030+1.1%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in Missouri · Every state · Compare with Ohio
SI-BONE leads with 94% of company spending on these surgeons in 2025, −1 pts on 2024.
In 2025, 4 companies reported engagement with Missouri’s surgeons worth $25K in consulting, speaking, meals and travel tied to these products, about $8,328 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.